Palomar Medical to Present at Leerink Swann Global Healthcare Conference in New York on February 13, 2013
01 2월 2013 - 3:34AM
Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a global leader
in laser and other light-based systems for aesthetic treatments,
today announced that Joseph Caruso, the Company's Chairman,
President and Chief Executive Officer and Paul Weiner, Chief
Financial Officer will present at the Leerink Swann Global
Healthcare Conference to be held February 13-14, 2013 at the
Waldorf-Astoria Hotel in New York. Senior management will make a
corporate presentation on February 13th at 11:00 a.m. ET and hold
one-on-one meetings with institutional investors to review the
Company's business strategy and recent corporate events.
Palomar will offer a live audio webcast of the presentation
which may be accessed at the Investor Relations section of the
Company's website at palomarmedical.com
About Palomar Medical Technologies, Inc.:
Palomar is a global leader in laser and other light-based systems
for aesthetic treatments. Palomar pioneered the optical hair
removal field, when, in 1997, it introduced the first high-powered
laser hair removal system. Since then, many of the major advances
in light-based hair removal have been based on Palomar
technology.
As a pioneer of fractional technology, Palomar is an owner of
fundamental intellectual property in this area. In December 2009,
Palomar received the first United States Food and Drug
Administration (FDA) clearance for the treatment of stretch marks
using a fractional non-ablative laser. In September 2010, Palomar
received the first FDA clearance for a fractional ablative and
fractional non-ablative combination treatment.
In December 2006, Palomar became the first company to receive a
510(k) over-the-counter (OTC) clearance from the FDA for a new,
patented, home-use, light-based hair removal device. In June 2009,
Palomar became the first company to receive a 510(k) OTC clearance
from the FDA for a new, patented, home-use, laser device for the
treatment of periorbital wrinkles. OTC clearance allows these
products to be marketed and sold directly to consumers without a
prescription. Palomar introduced the PaloVia™ Skin Renewing Laser™
in December 2010.
There are now millions of laser- and light-based aesthetic
procedures performed around the world every year in physician
offices, clinics, spas, salons, and homes. Palomar is testing many
new and exciting applications to further advance the aesthetic
market and other surgical applications.
For more information on Palomar and its products, visit
Palomar's website at palomarmedical.com. To continue receiving the
most up-to-date information and latest news on Palomar as it
happens, sign up to receive automatic e-mail alerts by going to the
About Palomar/Investors section of the website.
With the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements, including, but not limited to, statements relating to
new markets, future royalty amounts due from third parties,
development and introduction of new products, and financial and
operating projections. These forward-looking statements are neither
promises nor guarantees, but involve risk and uncertainties that
may individually or mutually impact the matters herein, and cause
actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but
are not limited to, results of future operations, technological
difficulties in developing or introducing new products, the results
of future research, lack of product demand and market acceptance
for current and future products, the effect of economic conditions,
challenges in managing joint ventures and research with third
parties and government contracts, the impact of competitive
products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained
for future products and additional applications, the results of
litigation, difficulties in collecting royalties, potential
infringement of third-party intellectual property rights, factors
affecting the Company's future income and resulting ability to
utilize its NOLs, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on
Form 10-K for the year ended December 31, 2011 and the Company's
quarterly reports on Form 10-Q. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to
release publicly the result of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
CONTACT: Kerry McAnistan
Investor Relations Assistant
Palomar Medical Technologies, Inc.
781-993-2411
ir@palomarmedical.com
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024